
Dr Janet Coller
Senior Lecturer
School of Biomedicine
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Dr Janet Coller is a Senior Lecturer in the Discipline of Pharmacology, the School of Medicine at the University of Adelaide. She has significant undergraduate teaching (into 6 courses) and administrative duties, including course coordination and Honours program coordination, accounting for 50% of her time. The remaining 50% is spent running her research program in clinical pharmaco- and immuno-genetics as head of the Clinical Pharmacogenomics Laboratory and member of the Cancer Treatment Toxicities Group
Cancer Treatment Toxicities Group
Our group members include undergraduate students, through to Honours and PhD, as well as postdoctoral researchers. We conduct research projects using cell culture models, transgenic rodents, and in patient cohorts (detailed below). Our mission is to improve cancer outcomes through personalising treatment and supportive care.
Available Research Projects
Research Project 1
Title: Gut microbiome composition as a predictive marker for cancer treatment outcomes
Project description: Patients with cancer are at high risk of microbiome dysbiosis (lack of bacterial diversity and/or overabundance of pathogenic species) due to frequent hospital visits, surgery, chemotherapy and radiation treatment, other medications (notably prophylactic antibiotics), changes in diet, and the presence of cancer itself. Having a diverse gut microbiota is considered protective against chemotherapy-induced infections, and pre-clinical work points to bacterial diversity as a key determinant of tumour response, gastrointestinal toxicity, and neuroinflammation. Thus the objective of this project is to explore links between microbiota, inflammatory responses, and chemotherapy treatment outcomes. Research techniques include mouse models of cancer treated with chemotherapy, bacterial gene sequencing, and a patient trial analysing longitudinal changes in microbiome composition following different cancer therapies.
Projects available for: Honours / HDR
Location: Helen Mayo Building
Research project start: Semester 1 and 2
Special requirements: Nil
Research Project 2
Title: Toll-like receptor 4 and cancer treatment toxicities
Project description: Drugs and radiation used to treat cancer commonly cause damage to the normal gastrointestinal lining, leading to adverse symptoms such as intestinal inflammation and ulceration. There are currently no effective preventative strategies and a lack of understanding surrounding the mechanisms initiating damage. Recently, the innate immunity receptor, Toll-like Receptor 4 (TLR4), has been proposed to play a role in cancer therapy-induced gastrointestinal damage. As such, this project will investigate the effects of TLR4 gene deletion, or pharmacological inhibition, on the development of gastrointestinal inflammation in response to chemotherapy. This project will use rodent models treated with irinotecan. Research techniques include histological analysis, immunofluorescence, real time PCR and small animal handling. Results of this study will provide direct evidence of TLR4 signalling in mediating this important side effect of therapy.
Projects available for: Third Year / Honours / HDR
Location: Helen Mayo Building
Research project start: Semester 1 and 2
Special requirements: Nil
Research Project 3
Title: Role of microbial ablation on diarrhoea risk during treatment with EGFR inhibitors for breast cancer
Project description: Breast cancers that overexpress the human epidermal growth factor receptor (HER2) are treated by targeted small molecule inhibitors such as neratinib. HER2 and other members of the growth factor family are also expressed in the intestines, and treatment with neratinib is associated with chronic low-grade enterocolitis. We have developed a rat model in conjunction with our industry partners to explore the relationship between the composition of resident microbes in the intestine and the risk of severe treatment-related diarrhoea. The project will explore how different antibiotics impact the microbiome and how this affects onset and severity of neratinib diarrhoea. Techniques will include histopathology, immunohistochemistry and mucosal barrier permeability analysis.
Projects available for: HDR (PhD and M.Phil)
Location: Helen Mayo Building
Research project start: Semester 1 and 2
Special requirements: Nil
-
Appointments
Date Position Institution name 2015 - ongoing Senior Lecturer University of Adelaide 2013 - 2014 Lecturer University of Adelaide 2008 - 2012 FTT Fricker Research Fellow University of Adelaide 2004 - 2007 Postdoctoral Researcher University of Adelaide -
Awards and Achievements
Date Type Title Institution Name Country Amount 2007 Research Award Young Tall Poppy Science Award Australian Institute of Policy Science Australia - 2006 Research Award ASCEPT Mid-Career Best Paper Award ASCEPT Australia - 2004 Research Award APSA New Investigator Award Australasian Pharmaceutical Science Association Australia - 2002 Research Award ASCEPT Denis Wade Johnson & Johnson New Investigators Award ASCEPT Australia - -
Education
Date Institution name Country Title 2013 - 2013 University of Adelaide Australia Graduate Certificate in Education (Higher Education) 1996 - 2000 University of Adelaide Australia PhD (Medicine) 1995 - 1995 University of Adelaide Australia Bachelor of Science (Honours Pharmacology) 1992 - 1994 University of Adelaide Australia Bachelor of Science -
Postgraduate Training
Date Title Institution Country 2002 - 2004 NHMRC CJ Martin Research Fellow University of Adelaide Australia 2000 - 2002 NHMRC CJ Martin Research Fellow Dr Margarete Fischer Bosch Institute of Clinical Pharmacology Germany -
Certifications
Date Title Institution name Country 2015 Dangerous Goods Certification World Courier Aust Pty Ltd Australia 2014 AQIS Quarantine Approved Premises (Classes 2 to 8) Accreditation Australian Government Department of Agriculture Australia 2014 First Aid Certification St John Ambulance Australia Australia -
Research Interests
-
Journals
-
Book Chapters
Year Citation 2016 Coller, J., Barratt, D., & Somogyi, A. (2016). Clinically significant interactions with anti-addiction agents. In M. Jann, S. Penzak, & L. Cohen (Eds.), Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 565-577). Switzerland: Spinger.
DOI2012 Somogyi, A., & Coller, J. (2012). Drugs against acute and chronic pain. In P. Anzenbacher, & U. Zanger (Eds.), Metabolism of Drugs and Other Xenobiotics (1 ed., pp. 403-428). Germany: Wiley.
DOI Scopus32008 Somogyi, A., & Coller, J. (2008). Pharmacogenomics and Pharmacogenetics. In An Integrated Compendium of Twenty Encyclopedias (pp. 1-20). United Kingdom: Eolss Publishers. -
Conference Papers
Year Citation 2018 Korver, S. K., Bowen, J. M., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R., . . . Coller, J. K. (2018). Personalised supportive care for patients receiving 5-fluorouracil (5-FU): analysis of multivariate SNP risk prediction for GI toxicity. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 58-59). WILEY. 2016 Hu, R. (2016). CYP3A5*3 and ABCB1 haplotype 61A-1199G-1236T-2677T/A-3435T are associated with dose-adjusted trough blood tacrolimus concentration in kidney transplant recipients. In ASCEPT-MPGPCR 2016. Melbourne, Australia. 2009 Somogyi, A. A., Gelston, E., Coller, J. K., White, J. M., & Schmidt, H. (2009). Methadone Inhibits CYP2D6 and UGT2B7 <i>In Vivo</i>: a Study using Codeine as the Substrate. In DRUG METABOLISM REVIEWS Vol. 41 (pp. 45-46). Lisbon, PORTUGAL: TAYLOR & FRANCIS INC.
WoS12009 Sallustio, B. C., Westley, I. S., Coller, J. K., Ward, M. B., Russ, G. R., & Morris, R. G. (2009). Frequency of Genetic Polymorphisms in the Promoter (C-24T), Exon 10 (G1249A) and Exon 28 (C3972T) Regions of <i>ABCC2</i> in Australian Renal Transplant Recipients and Donors. In THERAPEUTIC DRUG MONITORING Vol. 31 (pp. 656-657). Montreal, CANADA: LIPPINCOTT WILLIAMS & WILKINS. 2007 Sallustio, B. C., Davies, B. J., Herbert, M. K., Coller, J. K., Somogyi, A. A., & Milne, R. W. (2007). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 extensive and poor metabolisers. In THERAPEUTIC DRUG MONITORING Vol. 29 (pp. 478). Nice, FRANCE: LIPPINCOTT WILLIAMS & WILKINS. -
Conference Items
Year Citation 2019 Coller, J. K., Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., . . . Bowen, J. M. (2019). Predictors of severe gastrointestinal toxicity risk in patients treated with 5-fluorouracil-based chemotherapy: A validation study. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2017 Korver, S. K., Ball, I. A., Gibson, R. J., Logan, R. M., Karapetis, C. S., Keefe, D. M., . . . Coller, J. K. (2017). The Effect of Immune Genetic Variants on Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2017 Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., Richards, A., . . . Coller, J. K. (2017). Interleukin-1 Beta (<i>IL1B</i>) Genetic Variability is Predictive of Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2015 Dom, Z. I. M., Westley, I. S., Coller, J. K., Somogyi, A. A., & Sallustio, B. C. (2015). Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of mycophenolic acid in renal transplant recipients. Poster session presented at the meeting of Abstracts of the 2015 Golden Helix Symposium - Next Generation Pharmacogenomics, as published in Public Health Genomics. Karger.
DOI WoS12014 Li, Y., Coller, J., Hutchinson, M., Klein, K., Zanger, U., Currow, D., . . . Somogyi, A. (2014). Cyp2B6*6 Allele Alters Ketamine'S Pharmacokinetics In Chronic Pain Patients And Metabolism In Vitro. Poster session presented at the meeting of Drug Metabolism Reviews. Toronto, CANADA: Informa Healthcare.
DOI Europe PMC22013 Dom, M. Z., Coller, J. K., Somogyi, A. A., & Sallustio, B. C. (2013). Impact of Recipient and Donor Multidrug Resistance Protein 2 Genetic Variability on Mycophenolic Acid Pharmacokinetics Following Kidney Transplantation. Poster session presented at the meeting of THERAPEUTIC DRUG MONITORING. Salt Lake City, UT: LIPPINCOTT WILLIAMS & WILKINS. 2011 Somogyi, A. A., Coller, J. K., Foster, D. B. F., & Li, Y. (2011). ROLE OF CYP2B6 POLYMORPHISM IN THE METABOLISM AND PHARMACOKINETICS OF METHADONE ENANTIOMERS. Poster session presented at the meeting of BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. WILEY-BLACKWELL.
WoS1
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Co-Supervisor What impact could greenspace exposure have on lower respiratory outcomes? Doctor of Philosophy Doctorate Part Time Mrs Amanda Maddern 2023 Co-Supervisor Chronic abdominal pain in Australian adolescents and nature-based intervention Master of Philosophy (Medical Science) Master Part Time Mrs Trish Serocki 2019 Co-Supervisor Using Pharmacokinetic Principles to Improve the Safety of Tacrolimus in Kidney Transplant Recipients Doctor of Philosophy Doctorate Part Time Miss Mirabel Alonge -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2019 - 2023 Co-Supervisor The Role of TLR4 in Chemotherapy-Induced Toxicity, Immunity and Tumour Growth Doctor of Philosophy Doctorate Full Time Mrs Elise Ellen Crame 2018 - 2022 Co-Supervisor Exploring the Effects of Toll-Like Receptor 4 Antagonism on Gastrointestinal Mucositis and Tumour Activity Doctor of Philosophy Doctorate Full Time Miss Shu Yie Janine Tam 2017 - 2021 Co-Supervisor Exploration of the gut microbiome as a predictive factor for cancer treatment-induced gastrointestinal toxicity Doctor of Philosophy Doctorate Full Time Miss Kate Rebecca Secombe 2016 - 2020 Principal Supervisor Identifying potential genetic, phenotypic and epigenetic predictive markers in the Toll-like receptor/Interleukin-1 domain innate immune signalling pathway for severe gastrointestinal toxicity risk following 5-Fluorouracil-based therapy Doctor of Philosophy Doctorate Full Time Miss Samantha Kaitlyn Korver 2015 - 2019 Co-Supervisor Genetics of Tacrolimus Pharmacokinetics and Kidney Transplant Outcomes Doctor of Philosophy Doctorate Full Time Ms Rong Hu 2011 - 2017 Co-Supervisor Mycophenolic Acid Pharmacokinetics and Clinical Outcomes in Renal Transplantation: Effect of ABCC2 Haplotype Analysis and Distribution into Lymphocytes and Kidney Doctor of Philosophy Doctorate Full Time Mr Zaipul Izwan Md Dom 2010 - 2014 Co-Supervisor Pharmacogenetics of Ketamine Metabolism and Immunopharmacology of Ketamine Doctor of Philosophy Doctorate Full Time Mr Yibai Li 2010 - 2015 Co-Supervisor A Study Linking Toll-like Receptors and Irinotecan-induced Gastrointestinal Mucositis Doctor of Philosophy Doctorate Full Time Mrs Khloud Ghazi Fakiha 2009 - 2011 Co-Supervisor CNS Immune Signalling and Drug Addiction: Role of Interleukin-1 Beta Doctor of Philosophy Doctorate Full Time Mr Liang Liu 2008 - 2011 Co-Supervisor The Neuroimmunopharmacology of Alcohol Doctor of Philosophy Doctorate Full Time Miss Yue Wu 2005 - 2010 Co-Supervisor Pharmacogenomics of ABCB1 in Maintenance Pharmacotherapies for Opioid Dependence Doctor of Philosophy Doctorate Full Time Dr Daniel Barratt 2003 - 2008 Co-Supervisor The Stereoselective Pharmacokinetics of the Enantiomers of Perhexiline in Poor and Extensive Metabolisers of the Cytochrome P450 2D6 Doctor of Philosophy Doctorate Full Time Mr Benjamin Davies
-
Memberships
Date Role Membership Country 2016 - ongoing Member MASCC United States 2012 - ongoing Member PNIRS United States 2004 - ongoing Member APSA Australia 1998 - 2015 Member ISSX United States 1995 - ongoing Member ASCEPT Australia -
Editorial Boards
Date Role Editorial Board Name Institution Country 2012 - ongoing Board Member Frontiers in Pharmacogenetics - - 2007 - 2012 Board Member The Open Drug Metabolism Journal - -
Connect With Me
External Profiles